MedTrace Logo

Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

NCT04202536 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2019-12-17

No results posted yet for this study

Summary

A research study to observe the safety, efficacy and tolerability of switching from Tenofovir Disoproxil Fumarate to Besifovir dipivoxil maleate in patients with chronic hepatitis B

Conditions

  • Hepatitis B
  • Besifovir Dipivoxil Maleate
  • Tenofovir Disoproxil Fumarate

Interventions

DRUG

Besifovir Dipivoxil Maleate

Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®

DRUG

Tenofovir disoproxil fumarate(TDF)

300 mg tablet administered orally once daily Other Name: VIREAD®

Sponsors & Collaborators

  • IlDong Pharmaceutical Co Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2021-06-30
Completion
2021-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04202536 on ClinicalTrials.gov